SCHEMBL589799

SCHEMBL589799

CC(NC(=O)c1cc(Cl)cc(Br)c1NC(=O)C1CC(O)=NN1c1ncccc1Cl)C1CC1

nearest known ligand 0.38

Predicted protein targets (top 7)

geneUniProtsupporting neighboursconfidence
F10 P00742 2/20 0.37
IDO1 P14902 2/20 0.36
MALT1 Q9UDY8 11/20 0.36
NAMPT P43490 2/20 0.35
PSD A5PKW4 1/20 0.35
NPC1 O15118 1/20 0.34
RAB9A P51151 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL592361 0.93 IDO1 (0.37) F10IDO1MALT1NAMPTPSD
SCHEMBL590490 0.92 MALT1 (0.42) F10IDO1MALT1NAMPTNPC1
SCHEMBL591565 0.90 MALT1 (0.36) F10IDO1MALT1NAMPT
SCHEMBL590447 0.87 F10 (0.41) F10IDO1MALT1NAMPTNPC1
SCHEMBL15085602 0.86 IDO1 (0.33) F10IDO1MALT1NAMPTPSD
SCHEMBL590823 0.86 MALT1 (0.41) F10IDO1MALT1NAMPTNPC1
SCHEMBL1148202 0.86 IDO1 (0.34) F10IDO1MALT1NAMPT
SCHEMBL1148386 0.86 MALT1 (0.33) F10IDO1MALT1NAMPT
SCHEMBL15085577 0.86 IDO1 (0.33) F10IDO1MALT1NAMPT
SCHEMBL591460 0.85 MALT1 (0.33) F10IDO1MALT1NAMPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2093223-B1 PROCESS AND INTERMEDIATES FOR PRODUCTION OF AN ANTHRANILAMIDE COMPOUND ISHIHARA SANGYO KAISHA (JP) 2013-08-21 EP disclosed
US-8481744-B2 Process for producing anthranilamide compound ISHIHARA SANGYO KAISHA, LTD. (JP) 2013-07-09 US disclosed
EP-2264021-B1 PROCESS FOR PRODUCING AN ANTHRANILAMIDE COMPOUND ISHIHARA SANGYO KAISHA (JP) 2013-06-26 EP disclosed
US-8115006-B2 Process for producing anthranilamide compound ISHIHARA SANGYO KAISHA, LTD. (JP) 2012-02-14 US disclosed
US-20110034696-A1 PROCESS FOR PRODUCING ANTHRANILAMIDE COMPOUND ISHIHARA SANGYO KAISHA, LTD. (JP) 2011-02-10 US disclosed
EP-2264021-A1 PROCESS FOR PRODUCING AN ANTHRANILAMIDE COMPOUND ISHIHARA SANGYO KAISHA, LTD. (JP) 2010-12-22 EP disclosed
US-20100063293-A1 PROCESS FOR PRODUCING ANTHRANILAMIDE COMPOUND ISHIHARA SANGYO KAISHA ,LTD. (JP) 2010-03-11 US disclosed
EP-2093223-A1 PROCESS FOR PRODUCTION OF ANTHRANILAMIDE COMPOUND ISHIHARA SANGYO KAISHA, LTD. (JP) 2009-08-26 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100063293-A1 PROCESS FOR PRODUCING ANTHRANILAMIDE COMPOUND NAAA, AAAS, AADAC F10 1441/4885IDO1 1265/4885MALT1 1682/4885
US-20110034696-A1 PROCESS FOR PRODUCING ANTHRANILAMIDE COMPOUND SQOR, NOX5, NOX3 F10 934/4885IDO1 288/4885MALT1 3967/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.